Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study)
2007; Wiley; Volume: 62; Issue: 2 Linguagem: Inglês
10.1111/j.1742-1241.2007.01652.x
ISSN1742-1241
AutoresMyung‐Soo Choo, Chin Kyung Doo, K.-S. Lee,
Tópico(s)Urinary Tract Infections Management
ResumoInternational Journal of Clinical PracticeVolume 62, Issue 2 p. 191-196 Satisfaction with tolterodine: assessing symptom-specific patient-reported goal achievement in the treatment of overactive bladder in female patients (STARGATE study) M.-S. Choo, M.-S. Choo Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaSearch for more papers by this authorC. K. Doo, C. K. Doo Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaSearch for more papers by this authorK.-S. Lee, K.-S. Lee Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaSearch for more papers by this author M.-S. Choo, M.-S. Choo Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaSearch for more papers by this authorC. K. Doo, C. K. Doo Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, KoreaSearch for more papers by this authorK.-S. Lee, K.-S. Lee Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KoreaSearch for more papers by this author First published: 07 December 2007 https://doi.org/10.1111/j.1742-1241.2007.01652.xCitations: 22 Professor Kyu-Sung Lee, MD, PhD, Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul 135-710, KoreaTel.: + 82 2 3410 3554Fax: + 82 2 3410 3027Email: ksleedr@skku.edu Disclosure No commercial or other associations that might pose a conflict of interest in connection with this article for all authors. Clinical trial registration identifier We did not have a clinical trial registration identifier. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Summary Aims: Open-label study to evaluate the effect of tolterodine extended-release (ER) on symptom-specific patient-reported goal achievement (PGA) of overactive bladder (OAB) symptoms in females. Methods: Eligible patients who had frequency ≥ 8 and urgency ≥ 2 episodes per 24 h with or without urgency incontinence were treated with 12-week tolterodine ER (4 mg once daily). Primary end-point was the rate of PGA by a visual analogue scale compared with initial expectation with treatment. At baseline, patients were asked to set their personal goals for each OAB symptom with treatment. Secondary efficacy variables were changes in symptom severity, voiding diary and patient perception of bladder condition (PPBC), global impression of improvement (GII), and willingness to continue treatment. Results: A total of 56 patients were entered. The median rate of symptom-specific PGA and reductions in symptom severity were for frequency (60%, 45%), episodes of urgency 60%, 55%), urge incontinence (80%, 71%), nocturia (50%, 52%) and tenesmus (30%, 26%) after 12 weeks treatment. There was a significant improvement in all OAB symptoms in voiding diary. Thirty-five patients (62.5%) experienced an improvement of ≥ 2 points in PPBC. Thirty (53.6%) and 22 (39.3%) of patients reported much and little improvement of their symptoms in GII. A total of 41 (73.2%) patients wanted to continue taking the medication at the end of the study. Conclusions: Most OAB patients reported improvement of their OAB symptoms with 12-week tolterodine ER 4 mg treatment. There was a significant achievement of symptom-specific goal on the key OAB symptoms. But, PGA did not correlate with objective outcomes. Citing Literature Volume62, Issue2February 2008Pages 191-196 RelatedInformation
Referência(s)